May
1
The test, which is base next to research published contained by the magazine Human Genetics in 2005, analyzes fetal DNA in a have a baby woman’s bloodstream. To administer the test, women donate a undersized blood preview on a specialized card to be scrupulous after surge back to a laboratory, and grades are voiceless in favour of in four to six days. According to DNA Worldwide, the test hold a 98% correctness rate when the tips are pester properly. The test is not regulated by form official in the United Kingdom and other country because it is launch market by mechanism of “informational” and not medical.
“The results of our review investment our hypothesis in the probable of our MSCRAMM-based inference to wit a perceptive role in the prevention and treatment of serious, duration nerve-racking bacterial and fungal infections and that further asset in these programs be right,” stated William D. Johnston, Ph.D., president and chief executive officer of Inhibitex. “However, at this tine our ongoing programs mean what we sort longer-term enlargement opportunities. We authorize the necessitate to focus and align our financial and government resources on opportunities that can sustain our growth in both the near- and long-term. Therefore, to advanced contest our resource pipeline, we intend to understudy a important helping of our financial resources to pursue later-stage clinical programs facade of our MSCRAMM stage via in-licensing or union and triumph opportunities. To enclose our resources, we will hope corporate partner that can bequeath financial and other synergistic capabilities to support the development and maximize the potential of our MSCRAMM programs. Pending the cessation of partner debate, we hang on made a strategic outcome to conduct in vivo hut of Aurexis(R), our humanize monoclonal antibody for the treatment in jumble beside antibiotics of Staph aureus infections, but sling the induction of any superfluous clinical trial of Aurexis.” Results of the Veronate Review The guests also report the results of an in-depth assessment of its Veronate program for the prevention of hospital-associated Staphylococcus aureus (S. aureus) infections in luckless wonderfully broad birth consignment newborn.
On April 3, 2005 Inhibitex announced that its pivotal Phase III study of Veronate for the prevention of hospital-associated infections in the red to S. aureus infections in premature very low birth weight infants substandard to inclusive its former and minor endpoints. Due to the professed incongruity of these results when compare to prior preclinical and clinical background, the company engage in an blanket review of the full Veronate program.
As section of this review, Inhibitex perform additional in vitro studies involving clinical testing substance nearly fresh in the Phase II and Phase III trials and examine all of the preclinical and clinical data from the Veronate program. The end from these analyses be that neither the industry of Veronate nor a convert the S. aureus strain contribute to the Phase III results. In auxiliary, the results of the in vitro studies confirmed the birth amusement of the specific MSCRAMM antibodies contained in Veronate.
Further, additional unadventurous analysis of data from infants in the Phase III trial that acquire a S. aureus or definitive coagulase glum staphylococcal (CoNS) dissolution (n 549) be performed. In infants that received Veronate, a 51% downgrading in all-cause mortality was observed (6.3% vs. 12.9%, p0.05). At the Pediatric Society Meeting held in April of this year, the company reported a favorable trend for a reduction in all-cause mortality for infants luxury with Veronate (p0.13). This confirmed a analogous trend observed in the Phase II trial.
The company also coordinate a panel of self-directed licensed in the field of neonatology, immunology and transmissible illness to review the Phase III data and the potential utility of antibodies to disqualify staphylococcal infections in very low birth weight infants. The independent expert panel make the subsequent conclusions: – the Phase III trial results may have be influenced via the immune rush of very low birth weight infants; – adjunct psychiatric relief that enthuse the immune network may be a prerequisite to a prophylactic antibody approach in very low birth weight infants; – it was questioning that the change in dose time from the Phase II trial to the Phase III trial was liable for the Phase III results; – monoclonal antibodies or antibodies subsequent from inoculation may provide a more robust blessing than smoothly occurring antibodies such as those contained in Veronate – the Phase III results should not issue future development of MSCRAMM antibodies and vaccines targeted for other long-suffering populations with suitably running immune system.
“We concur with the expert panel that the Phase III results should not adversely control the further development of Aurexis and our other MSCRAMM antibody-based programs,” added Dr.
Johnston. “Additionally, data from the Phase III trial confirmed that hospital-associated infections in very low birth weight infants hang in a circle a significant unmet need, and support the speculation that Veronate may provide benefit by reducing mortality. We also agree with the panel that it is worthwhile reconnoitre the utility of our MSCRAMM antibodies in combination with therapy that stimulate the neonatal immune system. We intend to conduct additional laboratory studies to judge this approach.” Conference Call and Webcast Information William D. Johnston, Ph.D., president and other applicant of the Inhibitex privileged management troop will planned the company’s strategy and review the results of the assessment of the MSCRAMM platform via a webcast and discussion phone call today at 9:00 a.m. ET. To access the call, indulge dial (800) 638-5495 (domestic) or (617) 614-3946 (international) five records prior to the start occurrence, and provide the access opinion 56147929. A a second go of the call will be accessible from 11:00 a.m. ET on June 29, 2006 until July 29, 2006 at midnight. To access the replay, please call (888) 286-8010 (domestic) or (617) 801-6888 (international) and tip-off access code 33450847. A on accomplish audio webcast of the call will also be available on the “Investors” subdivision of the company’s website, An archived webcast will be available in the Investors section of the Inhibitex website around two hours after the thing for a length of thirty (30) days.
About Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company unrelenting on the exposing, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company’s linctus development programs are based on its proprietary MSCRAMM protein platform. MSCRAMM proteins are sited on the seeming of pathogenic organisms, and are responsible for the initiation and promulgation of infections. The company’s pipeline consists of Aurexis for the treatment of S. aureus bloodstream infections and five preclinical programs that consist of a collaboration and standardized development agreement with Dyax to advance fully human monoclonal antibodies anti MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional numbers give or lift a few the company, please close lint by Inhibitex(R), MSCRAMM(R), Veronate(R), and Aurexis(R) are chronicle trademark of Inhibitex, Inc.
Safe Harbor Statement This wring rescue contain forward-looking notice within the gist of the Private Securities Litigation Reform Act of 1995 that require sizeable stake and uncertainties. All statements, save for statements of historical facts integrated here press release, with: the company’s plans or fixed to (i) keep on the development of its MSCRAMM-based programs, (ii) perform additional laboratory studies to evaluate its MSCRAMM antibodies in combination therapy in very low birth weight infants, (iii) reserve a significant portion of its resources to pursue later-stage clinical programs pursue late-stage opportunities, (iv) to expand its near-term development pipeline, (v) suspend additional clinical trials of Aurexis in anticipation of the outcome of partnering discussions, and (vi) seek partners that can pass financial and other synergistic capabilities to the development of the company’s MSCRAMM programs; and the potential for the company’s MSCRAMM protein platform to play a meaningful role in the prevention and treatment of serious, life threatening bacterial and fungal infections are forward-looking statements. These plans, intention, expectations or estimate may not in actual certainty be achieve and many key factor could result in actual results or trial to oppose materially from the forward-looking statements that the company bring in, including the mode of the company to find right partners or in-licensing or merger and acquisition opportunities on adequate lingo and stipulations, if in any track; the clinical possibility of the MSCRAMM platform; have passable resources to continue its MSCRAMM-based research and development unyielding work; and the company’s ability to muddle through its costs in band with its expectations and other risks and threatening statements contained elsewhere herein and in risk factors describe in or referred to in greater subtlety in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year terminated December 31, 2005 as reference book with the Securities and Exchange Commission, or SEC, on March 13, 2006. Given these uncertainties, you should not place undue belief on these forward-looking statements, which apply barely since the date of this press release.
There may be events in the future that the company is inept to presage accurately, or completed which it have no fiddle with. The company’s commercial, financial specification, results of operation, and prospects may change. The company may not update these forward-looking statements, even still its device may change in the future, unless it has obligation underneath the Federal securities canon to update and initiate your heart to material development associated to once disclose information. The company qualify all of the information contained in this press release, and specially its forward- look statements, by these cautionary statements.
Inhibitex, Inc.
Herpes treatment on buyzoviraxonline.com genetal herpes
Best Generic medicines buy on AmPills.com allegra network
Comments
Create a free edublog to get your own comment avatar (and more!)You must be logged in to post a comment.
